Limited approaches such as single or few gene assays for the main drivers BCR-ABL1, JAK2, MPL and CALR can still serve as the method of choice in straightforward cases of MPN, but unusual clinico-pathological features, or absence of MPN driver mutations, should prompt more comprehensive testing. This evidence concerns the gene MPL and myeloproliferative neoplasm.